Author:
Kokudo Norihiro,Nakajima Junta,Hatano Etsuro,Numata Kazushi
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference11 articles.
1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr [Accessed 2010 Nov]
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–90
3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25–34
4. Bayer. Nexavar approved in Japan for the treatment of advanced liver cancer. [media release]. 2009 May 20 [online]. Available from URL: http://www.onyx-pharm.com/view.cfm/589/Nexavar-Approved-in-Japan-for-the-Treatment-of-Advanced-Liver-Cancer
5. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47(14): 2117–27
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献